Partitioned Survival and State Transition Models for Healthcare Decision Making in Oncology: Where Are We Now?

Dec 1, 2020, 00:00
10.1016/j.jval.2020.08.2094
https://www.valueinhealthjournal.com/article/S1098-3015(20)34356-4/fulltext
Title : Partitioned Survival and State Transition Models for Healthcare Decision Making in Oncology: Where Are We Now?
Citation : https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(20)34356-4&doi=10.1016/j.jval.2020.08.2094
First page : 1613
Section Title : METHODOLOGY
Open access? : No
Section Order : 1613

Objectives

Partitioned survival models (PSMs) are routinely used to inform reimbursement decisions for oncology drugs. We discuss the appropriateness of PSMs compared to the most common alternative, state transition models (STMs).

Methods

In 2017, we published a National Institute for Health and Care Excellence (NICE) Technical Support Document (TSD 19) describing and critically reviewing PSMs. This article summarizes findings from TSD 19, reviews new evidence comparing PSMs and STMs, and reviews recent NICE appraisals to understand current practice.

Results

PSMs evaluate state membership differently from STMs and do not include a structural link between intermediate clinical endpoints (eg, disease progression) and survival. PSMs directly consider clinical trial endpoints and can be developed without access to individual patient data, but limit the scope for sensitivity analyses to explore clinical uncertainties in the extrapolation period. STMs facilitate these sensitivity analyses but require development of robust survival models for individual health-state transitions. Recent work has shown PSMs and STMs can produce substantively different survival extrapolations and that extrapolations from STMs are heavily influenced by specification of the underlying survival models. Recent NICE appraisals have not generally included both model types, reviewed individual clinical event data, or scrutinized life-years accrued in individual health states.

Conclusions

The credibility of survival predictions from PSMs and STMs, including life-years accrued in individual health states, should be assessed using trial data on individual clinical events, external data, and expert opinion. STMs should be used alongside PSMs to support assessment of clinical uncertainties in the extrapolation period, such as uncertainty in post-progression survival.

Categories :
  • Cost-comparison, Effectiveness, Utility, Benefit Analysis
  • Decision Modeling & Simulation
  • Economic Evaluation
  • Health Policy & Regulatory
  • Reimbursement & Access Policy
  • Study Approaches
Tags :
  • cost-effectiveness analysis
  • modeling
  • partitioned survival
  • state transition model
Regions :
ViH Article Tags :